Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Behçet's disease wikipedia , lookup
Atherosclerosis wikipedia , lookup
Childhood immunizations in the United States wikipedia , lookup
Germ theory of disease wikipedia , lookup
Infection control wikipedia , lookup
African trypanosomiasis wikipedia , lookup
Globalization and disease wikipedia , lookup
Hepatitis B wikipedia , lookup
Kawasaki disease wikipedia , lookup
GHEC affiliate profile JA Tice August 5, 2014 Name Affiliations Narrative (brief; refer to detailed information on projects and publications below) Goals Selected projects and plans Collaborators (selected) 5 key publications Teaching Skills Substantive areas Jeffrey (Jeff) A. Tice, MD UCSF DGIM, CTSI, ICER, CTAF Twenty-three years’ experience in the empirical and modeled assessment of the costeffectiveness of dietary fat reduction, CAD screening and interventions, breast cancer, and hepatitis C. Currently, PI of a contract to provide systematic reviews underlying cost and value analyses of new technologies with the California Technology Assessment Forum (CTAF), a program of the Institute for Comparative Effectiveness Research (ICER). Expand awareness and utility of cost information in health care policy discussions in the United States Support UCSF global health economics capacity (via GHECon) California Technology Assessment Forum: Systematic reviews and cost analysis in support of a public forum making judgments about the clinical effectiveness and value of new medical technologies. Currently expanding our cost analysis of emerging therapies for hepatitis C. USPSTF: Cost-utility modeling of aspirin and statins for primary prevention of CAD. CHD Policy Model: Modeling the impact of homocysteine lowering therapy on CHD in the United States. CISNET: Collaboration with the BCSC on the optimal use of risk assessment to guide breast cancer screening technologies. Economists & modelers: D Ollendorf (ICER), S Pearson (ICER), S Earnshaw (UNC). Clinical & epidemiology researchers: L Goldman (CU), M Pignone (UNC), M Pletcher (UCSF). Ollendorf DA, Tice JA, Pearson SD. The Comparative Clinical Effectiveness and Value of Simeprevir and Sofosbuvir for Chronic Hepatitis C Virus Infection. JAMA internal medicine. May 5 2014. Tice JA, Ross E, Coxson PG, et al. Cost-effectiveness of vitamin therapy to lower plasma homocysteine levels for the prevention of coronary heart disease: effect of grain fortification and beyond. Jama. Aug 22-29 2001;286(8):936-943. Pignone M, Earnshaw S, Pletcher MJ, Tice JA. Aspirin for the primary prevention of cardiovascular disease in women: a cost-utility analysis. Arch Intern Med. Feb 12 2007;167(3):290-295. Pignone M, Earnshaw S, Tice JA, Pletcher MJ. Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis. Ann Intern Med. Mar 7 2006;144(5):326-336. Browner WS, Westenhouse J, Tice JA. What if Americans ate less fat? A quantitative estimate of the effect on mortality. Jama. Jun 26 1991;265(24):3285-3291. Established: Intervention and disease modeling, cost-effectiveness, systematic review. Desired: Costing, improved network meta-analysis. Established: Breast cancer, coronary artery disease, hepatitis C. Page 1 of 1